Working… Menu

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00026338
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : April 2, 2020
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group )

Tracking Information
First Submitted Date  ICMJE November 9, 2001
First Posted Date  ICMJE January 27, 2003
Last Update Posted Date April 2, 2020
Actual Study Start Date  ICMJE October 29, 2001
Actual Primary Completion Date September 17, 2004   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 28, 2011)
Overall survival [ Time Frame: 3 years ]
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 28, 2011)
  • Progression free survival [ Time Frame: 3 years ]
  • Quality of Life [ Time Frame: 3 years ]
    Canada, US and selected countries only
  • Response rates [ Time Frame: 3 years ]
    Complete and partial response only.
  • Toxicity [ Time Frame: 3 years ]
  • EGFR levels [ Time Frame: 3 years ]
    Correlate the expression oftissue EGFR levels (at diagnosis) with outcomes and response to treatment
  • Pharmacokinetics [ Time Frame: 3 years ]
    To measure trough levels of081-774 (Tarceva™) to determine population pharmacokinetics
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
Official Title  ICMJE A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill more tumor cells. It is not yet known if gemcitabine is more effective with or without erlotinib in treating pancreatic cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with and without erlotinib in treating patients who have unresectable locally advanced or metastatic pancreatic cancer.

Detailed Description


  • Compare the overall survival rate in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine with or without erlotinib.
  • Compare the progression-free survival rate in patients treated with these regimens.
  • Compare the quality of life of patients treated with these regimens.
  • Compare the response rate and response duration in patients treated with these regimens.
  • Compare the nature, severity, and frequency of toxic effects of these regimens in these patients.
  • Correlate the expression of tissue epidermal growth factor receptor levels at diagnosis with outcome and response in patients treated with these regimens.
  • Determine the pharmacokinetics of erlotinib in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to participating center, extent of disease (locally advanced vs metastatic), and ECOG performance status (0-1 vs 2). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 of course 1 only, which lasts 8 weeks, and on days 1, 8, and 15 of all subsequent courses, which last 4 weeks each. Patients also receive 1 of 2 doses of oral erlotinib once daily.
  • Arm II: Patients receive gemcitabine as in arm I and 1 of 2 doses of oral placebo once daily.

Treatment continues in both arms in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, on day 29 of course 1, on day 1 of all subsequent courses, at 4 weeks after study, and then every 12 weeks until disease progression.

Patients are followed at 4 weeks and then every 12 weeks thereafter.

PROJECTED ACCRUAL: A total of 800 patients (400 per treatment arm) will be accrued for this study within 11 months.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Pancreatic Cancer
Intervention  ICMJE
  • Drug: erlotinib hydrochloride
    150 mg po daily
  • Drug: gemcitabine hydrochloride
    1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
Study Arms  ICMJE
  • Active Comparator: OSI-774 plus Gemcitabine
    • Drug: erlotinib hydrochloride
    • Drug: gemcitabine hydrochloride
  • Active Comparator: Placebo plus gemcitabine
    Intervention: Drug: gemcitabine hydrochloride
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 28, 2011)
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE February 10, 2009
Actual Primary Completion Date September 17, 2004   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE


  • Histologically or cytologically confirmed adenocarcinoma of the pancreas
  • Locally advanced or metastatic disease that is considered unresectable
  • No known CNS metastases



  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • Absolute granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin less than 2 times upper limit of normal (ULN)
  • AST and/or ALT less than 2 times ULN (5 times ULN if liver metastases present)


  • Creatinine less than 1.5 times ULN


  • No uncontrolled high blood pressure
  • No unstable angina
  • No congestive heart failure
  • No myocardial infarction within the past year
  • No cardiac ventricular arrhythmias requiring medication


  • No gastrointestinal (GI) tract disease resulting in an inability to take oral medication such as uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)
  • No post-surgical malabsorption characterized by:

    • Uncontrolled diarrhea that results in weight loss and vitamin deficiency OR
    • Requires IV hyperalimentation
    • Pancreatic enzyme supplementation allowed provided that the above criteria are not met


  • No ocular inflammation or infection unless fully treated prior to study
  • No significant ophthalmologic abnormalities, including the following:

    • Severe dry eye syndrome
    • Sjogren's syndrome
    • Keratoconjunctivitis sicca
    • Severe exposure keratopathy
    • Disorders that would increase the risk for epithelium-related complications (e.g., bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis)


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No serious active infection
  • No other serious underlying medical, psychological, or geographical condition that would preclude study participation
  • No prior allergic reaction to compounds with similar chemical or biologic composition to erlotinib
  • No other prior malignancy within the past 5 years except cancer in situ or basal cell or squamous cell skin cancer


Biologic therapy:

  • No concurrent biologic therapy or immunotherapy


  • No prior chemotherapy except fluorouracil (with or without leucovorin calcium) or gemcitabine administered concurrently with radiotherapy as a radiosensitizer
  • No other concurrent cytotoxic chemotherapy

Endocrine therapy:

  • Not specified


  • See Chemotherapy
  • At least 4 weeks since prior radiotherapy and recovered
  • Prior radiotherapy for local disease allowed if evidence of disease progression has occurred
  • No concurrent radiotherapy


  • See Disease Characteristics
  • At least 2 weeks since prior major surgery
  • No concurrent ophthalmic surgery


  • No prior epidermal growth factor receptor inhibitors
  • At least 2 weeks since prior investigational drug
  • No other concurrent investigational drugs during and for at least 30 days after study
  • No other concurrent anti-cancer therapy
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 120 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Belgium,   Brazil,   Canada,   Chile,   China,   Germany,   Greece,   Hong Kong,   Israel,   Italy,   Mexico,   New Zealand,   Poland,   Romania,   Singapore,   United Kingdom,   United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00026338
Other Study ID Numbers  ICMJE PA3
CAN-NCIC-PA3 ( Other Identifier: PDQ )
OSI-CAN-NCIC-PA3 ( Other Identifier: OSI )
CDR0000069020 ( Other Identifier: PDQ )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Canadian Cancer Trials Group ( NCIC Clinical Trials Group )
Study Sponsor  ICMJE NCIC Clinical Trials Group
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Malcolm J. Moore, MD Princess Margaret Hospital, Canada
PRS Account Canadian Cancer Trials Group
Verification Date March 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP